# A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

> **NCT06010667** · — · NOT_YET_RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Envafolimab

## Key facts

- **NCT ID:** NCT06010667
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06010667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06010667, "A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06010667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*